Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 690-692

  Drew, Richard H ^a,b,c  

^a CAMPBELL UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Candida albicans; Invasive candidiasis; Non albicans Candida

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; FLUCONAZOLE; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; DEMOGRAPHY; DRUG CHOICE; HUMAN; INFECTION RISK; NEUTROPENIA; NON ALBICANS CANDIDA; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; CANDIDIASIS; FLUCONAZOLE; HUMANS; RISK ASSESSMENT;

EID: 34247197085     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K051     Document Type: Review

References (15)

1. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43(suppl):S3-14.
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.
3. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5.
4. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in non-neutropenic patients. Ann Pharmacother 2007;41:568-73. Epub 20 Mar 2007. DOI 10.1345/aph.1H516
5. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
6. Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Micro Infect Dis 2003;22:470-4.
7. Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004;10(suppl 1):11-23.
8. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-43.
9. Fluckiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. Swiss Medical Wkly 2006;136:447-63.
10. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54.
11. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-60.
12. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-control study. Antimicrob Agents Chemother 2005;49:4555-60.
13. Almirante B, Rodriguez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006;44:1681-5.
14. Weinberger M, Leibovici L, Perez S, et al. Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 2005;61:146-54.
15. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50:56-65.